Search

Background/Objectives : Aortic pulse wave velocity (aPWV) is a well-established surrogate marker of arterial stiffness. The Antares algorithm offers a method for determining aPWV from oscillometric blood pressure waveforms without requiring additional inputs. This prospective study aimed to evaluate the association and prognostic value of aPWV, determined by Antares, in predicting major adverse cardiovascular events (MACE). Methods : In total, 240 patients (median age 69, 25.4% female) underwent oscillometric blood pressure measurements, from which aPWV was calculated using the Antares algorithm. MACE, comprising myocardial infarction, stroke, or all-cause mortality, occurred in 19.2% of patients during a median follow-up of 43 months. Survival analyses were performed using continuous aPWV values, a 10 m/s threshold, and aPWV quartiles. Kaplan-Meier curves and log-rank tests were used to compare survival across aPWV groups. Cox proportional hazards models were applied to assess the independent predictive value of aPWV. Results : Patients with aPWV < 10 m/s showed significantly higher event-free survival compared to those with aPWV ≥ 10 m/s (log-rank p = 0.044). Quartile analysis reinforced this, with the highest event rate in the highest aPWV quartile (log-rank p < 0.01). Multivariable analysis confirmed aPWV as an independent predictor of MACE (HR per 1 m/s: 1.24, 95% CI: 1.08-1.41; HR per 1 SD: 1.53, 95% CI: 1.17-2.00, p = 0.002). Adding aPWV to a risk model improved predictive accuracy (C-index 0.68 to 0.71). Conclusions : In the investigated cohort, aPWV derived using the Antares algorithm is an independent predictor of cardiovascular events. This non-invasive approach is promising for improving simple outpatient risk stratification and targeting preventive measures.

Background: In cardiology, cardiac output (CO) is an important parameter for assessing cardiac function. While invasive thermodilution procedures are the gold standard for CO assessment, transthoracic Doppler echocardiography (TTE) has become the established method for routine CO assessment in daily clinical practice. However, a demand persists for non-invasive approaches, including oscillometric pulse wave analysis (PWA), to enhance the accuracy of CO estimation, reduce complications associated with invasive procedures, and facilitate its application in non-intensive care settings. Here, we aimed to compare the TTE and oscillometric PWA algorithm Antares for a non-invasive estimation of CO., Methods: Non-invasive CO data obtained by two-dimensional TTE were compared with those from an oscillometric blood pressure device (custo med GmbH, Ottobrunn, Germany) using the integrated algorithm Antares (Redwave Medical GmbH, Jena, Germany). In total, 59 patients undergoing elective cardiac catheterization for clinical reasons (71±10 years old, 76% males) were included. Agreement between both CO measures were assessed by Bland-Altman analysis, Student's t-test, and Pearson correlations., Results: The mean difference in CO was 0.04 ± 1.03 l/min (95% confidence interval for the mean difference: -0.23 to 0.30 l/min) for the overall group, with lower and upper limits of agreement at -1.98 and 2.05 l/min, respectively. There was no statistically significant difference in means between both CO measures (P = 0.785). Statistically significant correlations between TTE and Antares CO were observed in the entire cohort (r = 0.705, P<0.001) as well as in female (r = 0.802, P<0.001) and male patients (r = 0.669, P<0.001)., Conclusions: The oscillometric PWA algorithm Antares and established TTE for a non-invasive estimation of CO are highly correlated in male and female patients, with no statistically significant difference between both approaches. Future validation studies of the Antares CO are necessary before a clinical application can be considered., Competing Interests: A.S. has part‐time obligations in Redwave Medical GmbH. M.D. has received equipment for research projects from custo med GmbH and funding for research projects from Redwave Medical GmbH. S.R. has received equipment for research projects from custo med GmbH. S.E. has received equipment for research projects from custo med GmbH. J.B. has interest in Redwave Medical GmbH, and has received equipment and lecture fees from IEM GmbH, BPLab, SMT medical GmbH & Co., SOT Medical Systems and Tensiomed. All other authors have no conflict of interest to state. Redwave Medical GmbH is patent holder for pulse wave analysis in oscillometric pulse waves that are recorded during inflation and deflation of a cuff (patent no DE 10 2017 117 337 B4) and provided information about the algorithm requested by the authors. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2024 Stäuber et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Background: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations., Methods: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices., Results: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice., Conclusions: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension., Competing Interests: Disclosures A.P. Avolio is a member of the Scientific Advisory Board of CardieX. P. Boutouyrie has participated in the past in the validation of multiple devices, among them Popmètre and WITHINGS Body Cardio. P. Boutouyrie has research grants with WITHINGS for the development of connected health devices. P. Boutouyrie, P. Segers, and R.M. Bruno are involved as researchers in an H2020 project working on the development of an integrated silicon photonics-based device that aims to measure pulse wave velocity. S. Laurent received research grants and honoraria as a speaker or chairperson and has been on the advisory board of Servier Laboratories, SOM Biotech, and WITHINGS. J. Baulmann has an interest in Redwave Medical GmbH and received equipment and lecture fees from IEM GmbH, BPLab, SMT Medical GmbH & Co, SOT Medical Systems, and Tensiomed. J.A. Chirinos received University of Pennsylvania research grants from the National Institutes of Health, Fukuda-Denshi, Bristol-Myers Squibb, Microsoft, and Abbott. J.A. Chirinos was named inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites for the treatment of heart failure and preserved ejection fraction and patent applications for the use of biomarkers in heart failure. J.A. Chirinos received payments for editorial roles from the American Heart Association, the American College of Cardiology, and Wiley. J.A. Chirinos received research device loans from ATCOR Medical, Fukuda-Denshi, Unex, Uscom, NDD Medical Technologies, Microsoft, and MicroVision Medical. S.S. Daskalopoulou is a cofounder of the start-up PLAKK that aims to identify individual atherosclerotic plaque instability and stroke risk using artificial intelligence methods. C.C. Mayer is an inventor (not holder) of a patent that is partly used in the ARCSolver algorithm in the Mobil-O-Graph 24h PWA Monitor (IEM GmbH). A.E. Schutte received speaker honoraria from Servier, Novartis, Abbott, Sanofi, Omron, Aktiia, and Medtronic. E.M. Urbina was on the Data Safety Monitoring Board of Astellas, Inc, and received an honorarium from Targus Medical, Inc. I. Tan was an employee of ATCOR Medical. E. Bianchini is a cofounder of QUIPU s.r.l., a spin-off company of the Italian National Research Council and the University of Pisa developing software for medical devices.

Background: Obesity is a global health concern and risk factor for cardiovascular disease. The assessment of central blood pressure (cBP) has been shown to improve prediction of cardiovascular events. However, few studies have investigated the impact of obesity on cBP in adults, and invasive data on this issue are lacking. This study aimed to evaluate cBP differences between patients with and without obesity, identify cBP determinants, and evaluate the accuracy of the algorithm Antares for non-invasive cBP estimation., Methods: A total of 190 patients (25% female; 39% with BMI ≥30kg/m2; age: 67±12 years) undergoing elective cardiac catheterization were included. cBP was measured invasively and simultaneously estimated non-invasively using the custo screen 400 device with integrated Antares algorithm., Results: No significant cBP differences were found between obese and non-obese patients. However, females, especially those with obesity, had higher systolic cBP compared to males (P<0.05). Multiple regression analysis showed that brachial mean arterial pressure, pulse pressure, BMI, and heart rate predicted cBP significantly (adjusted R2 = 0.82, P<0.001). Estimated cBP correlated strongly with invasive cBP for systolic, mean arterial, and diastolic cBP (r = 0.74-0.93, P<0.001) and demonstrated excellent accuracy (mean difference <5 and SD <8 mmHg)., Conclusions: This study discovered no significant difference in cBP between obese and non-obese patients. However, it revealed higher cBP values in women, especially those with obesity, which requires further investigation. Additionally, the study highlights Antares' effectiveness in non-invasively determining cBP in obese individuals. This could improve the diagnosis and treatment of hypertension in this special patient population., Competing Interests: The authors have read the journal’s policy and have the following competing interests: Alexander Stäuber has part‐time obligations in Redwave Medical GmbH. Marcus Dörr has received equipment for research projects from custo med GmbH and funding for research projects from Redwave Medical GmbH. Stefan Richter has received equipment for research projects from custo med GmbH. Siegfried Eckert has received equipment for research projects from custo med GmbH. Johannes Baulmann has interest in Redwave Medical GmbH, and has received equipment and lecture fees from IEM GmbH, BPLab, SMT medical GmbH & Co., SOT Medical Systems and Tensiomed. All other authors have no conflict of interest to state. Redwave Medical GmbH is patent holder for pulse wave analysis in oscillometric pulse waves that are recorded during inflation and deflation of a cuff (patent no DE 10 2017 117 337 B4) and provided information about the algorithm requested by the authors. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2023 Stäuber et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

This follow-up study assessed the impact of a nitrate-rich diet on salivary nitrate/nitrite levels and the recovery of therapy-induced vascular impairments in a cohort of 39 periodontitis patients treated by standard subgingival mechanical plaque removal (PMPR). At baseline, saliva samples for nitrate/nitrite analysis were collected, and peripheral/central blood and augmentation pressure was documented using the Arteriograph recording system. Immediately after, PMPR vascular parameters were reassessed. All study patients received a randomly allocated supply of a lettuce beverage to be consumed for 14 days, containing either a daily dosage of 200 mg nitrate (test group, n = 20) or being void of nitrate (placebo group, n = 19). At day 14, salivary and vascular parameters were reassessed. Initial salivary and vascular parameters did not differ significantly between the groups. PMPR impaired all vascular parameters in both groups with no differences between the groups. At day 14, salivary nitrate/nitrite levels of the test group were significantly elevated compared to baseline. All vascular parameters had significantly recovered from the impairment inflicted by PMPR. In the placebo group, by contrast, salivary parameters did not differ significantly from baseline, and the recovery of impaired vascular parameters was restricted to a significant improvement of diastolic blood pressure. Correlation analysis identified a significant inverse correlation between salivary nitrate/nitrite sum and central/peripheral blood pressure and augmentation pressure. In conclusion, the data of this subanalysis suggest that increasing salivary nitrate/nitrite levels by a diet rich in nitrate may improve recovery of therapy-induced vascular impairments after PMPR., Competing Interests: The authors declare that they have no conflict of interest., (Thieme. All rights reserved.)

Introduction: Antares is a pulse wave analysis (PWA) algorithm designed to allow a non-invasive estimation of central (aortic) blood pressure (cBP) using automated oscillometric blood pressure (BP) devices. Diabetes may affect elastic and muscular arteries differently, resulting in disparate pulse wave characteristics in central and peripheral arteries, which may limit the accuracy of PWA devices. The aim of our study was to evaluate the accuracy of Antares for estimating cBP as compared with invasively measured cBP in patients with type 2 diabetes., Research Design and Methods: In this study, consecutive patients undergoing elective coronary angiography were recruited between November 2017 and September 2020. In 119 patients with type 2 diabetes, cBP was measured invasively and simultaneously determined non-invasively using the custo screen 400 device with the integrated Antares algorithm., Results: The mean difference between the estimated and invasively measured cBP was 1.2±6.3 mmHg for central systolic BP (cSBP), 1.0±4.3 mmHg for central mean arterial pressure (cMAP) and 3.6±5.7 mmHg for central diastolic BP (cDBP). High correlations were found between estimated cBP and invasively measured cBP (cSBP: r=0.916; cMAP: r=0.882; cDBP: r=0.791; all p<0.001)., Conclusions: The present study suggests that the Antares algorithm incorporated into the custo screen 400 device can estimate cBP with high accuracy turning a conventional oscillometric BP device into a type II device for the non-invasive estimation of cBP, which is applicable in patients with type 2 diabetes. Integration of Antares into commercially available BP devices could facilitate the introduction of cBP into routine clinical practice as a part of disease and risk management., Competing Interests: Competing interests: AS has part‐time obligations in Redwave Medical GmbH. SE has received equipment for research projects from custo med. MD has received equipment for research projects from custo med and funding for research projects from Redwave Medical GmbH. JB has interest in Redwave Medical GmbH and has received equipment and lecture fees from IEM GmbH, BPLab, SMT medical GmbH & Co, SOT Medical Systems and Tensiomed. Redwave Medical GmbH had no role in the design, execution or interpretation of the study. Redwave Medical GmbH provided information about the algorithm requested by the authors., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)